Literature DB >> 31605160

Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: a multi-centre cross-sectional study.

Kanon Takahashi1, Tetsuhiro Yoshino2, Yasuhito Maki3, Kan'ichiro Ishiuchi3, Takao Namiki4, Keiko Ogawa-Ochiai5, Kiyoshi Minamizawa6, Toshiaki Makino3, Tomonori Nakamura1, Masaru Mimura2, Kenji Watanabe7.   

Abstract

Liquorice [main ingredient, glycyrrhizin (GL)] is widely used as a food sweetener and herbal medicine. Occasionally, liquorice consumption causes pseudoaldosteronism as a side effect which causes oedema, hypokalaemia, and hypertension due to hyperactivity of mineral corticoid receptor. We aimed to detect GL metabolites in human blood and urine samples and to determine the pathological relationship between GL metabolites and pseudoaldosteronism. For this multi-centre, retrospective, cross-sectional study, we recruited patients who had visited Center for Kampo Medicine in Keio University Hospital, Department of Japanese Oriental (Kampo) Medicine in Chiba University Hospital, Clinic of Japanese Oriental (Kampo) Medicine in Kanazawa University Hospital, and Department of Oriental Medicine in Kameda Medical Center from November 2011 to July 2018. We collected laboratory data including concentration of serum potassium, plasma activity of renin and aldosterone, and residual blood and/or urine samples of participants who had experienced symptoms/signs of pseudoaldosteronism in the form of increase in blood pressure and occurrence or aggregation of oedema while taking liquorice-containing herbal preparations, and measured GL metabolites using a highly selective liquid chromatography tandem mass spectrometer system. We registered 97 participants (mean age 60 ± 15 years; male:female 14:83). 18β-glycyrrhetinic acid (GA) was detected in 67 serum samples (median 122 nM, range 5 nM-1.8 µM) and 18β-glycyrrhetyl-3-O-sulfate (compound 3) in 68 samples (median 239 nM, range 2 nM-4.2 µM). 3-Monoglucuronyl 18β-glycyrrhetinic acid, 22α-hydroxy-18β-glycyrrhetyl-3-O-sulfate-30-glucuronide, 22α-hydroxy-18β-glycyrrhetyl-3-O-sulfate, and GL itself were not or rarely detected. We could not find any correlation between blood pressure or peripheral oedema and serum concentration of GL metabolites. Sulfotransferase 2A1 catalysed the metabolic reaction of GA to compound 3, a major GL metabolite in human blood. High serum concentration of compound 3 was related to lower renin, aldosterone, and potassium levels, suggesting a pathological relationship between compound 3 and liquorice-induced pseudoaldosteronism. This is the first study to identify the association between a novel metabolite, compound 3, and the incidence of pseudoaldosteronism, highlighting it as a promising biomarker.

Entities:  

Keywords:  Glycyrrhizin; Kampo medicine; Liquorice; Side effect

Year:  2019        PMID: 31605160     DOI: 10.1007/s00204-019-02588-2

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  4 in total

1.  Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule.

Authors:  Xiao-Fang Lan; Olajide E Olaleye; Jun-Lan Lu; Wei Yang; Fei-Fei Du; Jun-Ling Yang; Chen Cheng; Yan-Hong Shi; Feng-Qing Wang; Xue-Shan Zeng; Nan-Nan Tian; Pei-Wei Liao; Xuan Yu; Fang Xu; Ying-Fei Li; Hong-Tao Wang; Nai-Xia Zhang; Wei-Wei Jia; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2021-04-30       Impact factor: 7.169

2.  Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines.

Authors:  Chuan Li; Wei-Wei Jia; Jun-Ling Yang; Chen Cheng; Olajide E Olaleye
Journal:  Acta Pharmacol Sin       Date:  2022-09-16       Impact factor: 7.169

3.  Identification of an Alternative Glycyrrhizin Metabolite Causing Liquorice-Induced Pseudohyperaldosteronism and the Development of ELISA System to Detect the Predictive Biomarker.

Authors:  Kan'ichiro Ishiuchi; Osamu Morinaga; Tetsuhiro Yoshino; Miaki Mitamura; Asuka Hirasawa; Yasuhito Maki; Yuuna Tashita; Tsubasa Kondo; Kakuyou Ogawa; Fangyi Lian; Keiko Ogawa-Ochiai; Kiyoshi Minamizawa; Takao Namiki; Masaru Mimura; Kenji Watanabe; Toshiaki Makino
Journal:  Front Pharmacol       Date:  2021-05-17       Impact factor: 5.810

Review 4.  Adverse Effects of Kampo Medicines.

Authors:  Yutaka Shimada
Journal:  Intern Med       Date:  2021-02-08       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.